# A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

> **NCT06626464** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]Elpipodect

## Key facts

- **NCT ID:** NCT06626464
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-13
- **Primary completion:** 2022-07-08
- **Final completion:** 2022-07-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626464, "A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06626464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*